PharmaEssentia
28
3
7
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.6%
1 terminated/withdrawn out of 28 trials
92.9%
+6.4% vs industry average
21%
6 trials in Phase 3/4
15%
2 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (28)
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Role: collaborator
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
Role: collaborator
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Role: collaborator
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Role: lead
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Role: lead
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Role: lead
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Role: lead
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Role: lead
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Role: lead
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
Role: lead
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
Role: lead
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
Role: lead
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Role: lead
A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers
Role: lead
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Role: collaborator
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp
Role: lead
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
Role: collaborator
Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
Role: collaborator
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Role: lead
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Role: collaborator